Comprehensive Evaluation of Drug Selection for Sequential Treatment of Neuromyelitis Optica Spectrum Disorders with Monoclonal Antibodies

OBJECTIVE To conduct a comprehensive clinical evaluation of 5 monoclonal antibodies in sequential treatment of neuromyelitis optica spectrum disorders and provide reference for clinical drug decision.

METHODS According to "Quick Guideline for Drug Evaluation and Selection in Chinese Medical Institutions(Second Edition)", combined with drug instructions, clinical treatment guidelines, and relevant literature, 5 monoclonal antibodies(Rituximab, Satralizumab, Inebilizumab, Eculizumab and Tocilizumab) were assigned and evaluated from 5 dimensions of pharmaceutical properties, efficacy, safety, economy and other attributes.

RESULTS The comprehensive scores for the monoclonal antibody drugs were evaluated as follows: Rituximab received 71.05 points, Eculizumab received 68.11 points, Satralizumab received 67.67 points, Inebilizumab received 65.28 points, and Tocilizumab received 58.09 points. Eculizumab, Satralizumab, and Inebilizumab each excelled in different attributes, but they lagged behind Rituximab in terms of economic viability.

CONCLUSION Rituximab is a highly recommended drug and is suggested to be kept in the drug usage catalog of medical institutions. Eculizumab, Satralizumab, and Inebilizumab may be considered depending on the characteristics of the patient population and the availability of alternative drugs. Tocilizumab is not recommended for the sequential treatment of neuromyelitis optica spectrum disorders.